UPDATE: Citi Downgrades Gilead Sciences (GILD) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Gilead Sciences (GILD) PT Lowered to $87 at Cantor Fitzgerald
February 12, 2019 7:14 AM ESTCantor Fitzgerald analyst Alethia Young lowered the price target on Gilead Sciences (NASDAQ: GILD) to $87.00 (from $92.00) while maintaining a Overweight rating after speaking with management.
STELLAR3 is set to read out in 2Q, and Cantor Fitzgerald has increased caution after the F4... More
Gilead Sciences (GILD) NASH Expectations Were Low, RBC Says; PT Trimmed to $84
February 12, 2019 6:53 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Gilead Sciences (NASDAQ: GILD) to $84.00 (from $89.00) while maintaining a Outperform rating after the company announced its first ph.III study of selonsertib in NASH, STELLAR 4, failed.
"... we believe expectations were low... More
UPDATE: Wells Fargo Downgrades Gilead Sciences (GILD) to Market Perform
February 12, 2019 1:33 AM EST(Updated - February 12, 2019 3:29 AM EST)
(updated to add analyst comment)
Wells Fargo downgraded Gilead Sciences (NASDAQ: GILD) from Outperform to Market Perform with a price target of $68.00 (from $95.00).
The analyst comments "While we see limited downside risk... More
